【摘要】 目的:探讨DNA甲基转移酶(DNA methyltransferase,DNMT1)与EZH2在急性髓系白血病(acute myeloid leukemia,AML)中的表达及其相关性。方法:采用荧光定量PCR(fluorescence quantitative PCR,FQ-PCR)检测大连医科大学附属第二医院2014年1月至2015年1月50例初治AML患者骨髓细胞中DNMT1与EZH2 m RNA的表达水平,分析DNMT1表达水平与临床特征和预后的关系以及与EZH2的相关性。结果:50例AML患者骨髓细胞中DNMT1 m RNA的表达显著高于30例正常供者(2.72±0.73 vs.0.89±0.27,P<0.01);EZH2的表达水平也显著高于正常供者(4.39±1.06 vs.1.87±0.33,P<0.01);EZH2与DNMT1的表达水平呈显著正相关(r=0.51,P=0.002);DNMT1表达水平与外周血幼稚细胞比例≥60%(P<0.05)、WBC≥50×109/L(P<0.05)呈显著相关;DNMT1高表达组患者中位生存时间15个月(95%CI为9~19个月),显著低于DNMT1低表达组患者的32个月(95%CI为27~40个月,P=0.006)。结论:DNMT1和EZH2在AML患者中均高表达,两者表达水平呈正相关,DNMT1与AML患者预后不良相关。更多还原

【Abstract】 Objective: To investigate the relationship between DNA methyltransferase(DNMT1) and EZH2 gene expression levels and their clinical significance in patients with acute myeloid leukemia(AML). Methods: The m RNA expression levels of DNMT1 and EZH2 in50 AML cases and 30 healthy controls were quantified through real-time PCR. The relationship among DNA methyltransferase(DNMT1)and EZH2, clinicopathological factors, and prognosis was analyzed. Results: The m RNA expression of DNMT1 in the AML cases(2.72±0.73) was significantly higher than that in the healthy controls(0.89±0.27)(P<0.01). The m RNA expression of EZH2 in the AML cases(4.39±1.06) was also significantly higher than that in the healthy controls(1.87±0.33)(P<0.01). The expression of DNMT1 was positively associated with that of EZH2(r=0.51, P=0.002). The expression of DNMT1 was also associated with PB% and WBC ≥50 × 10~9/L(P<0.05). The overall survival of the group with a high-m RNA-expressing DNMT1 was 15 months(95% CI=9-19 months). This period was significantly shorter than that of the group with low-m RNA-expressing DNMT1(32 months, 95% CI=27-40 months; P=0.006). Conclusion: DNMT1 and EZH2 expression levels were downregulated. These levels were associated with poor AML prognosis. The expression of DNMT1 was also positively associated with that of EZH2.更多还原